FDA guidance
Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet
FDA guidance · Draft · issued Apr 15, 2022
Key facts
| Title | Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet |
|---|---|
| Status | Draft |
| Issue date | Apr 15, 2022 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research, Office of New Drugs, Center for Biologics Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2021-D-1238 |
| Comments close | Jun 14, 2022 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents